Gad Soffer Sells 7,000 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Gad Soffer sold 7,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $15.00, for a total value of $105,000.00. Following the completion of the transaction, the executive vice president now directly owns 166,342 shares in the company, valued at approximately $2,495,130. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Atara Biotherapeutics, Inc. (ATRA) traded up $0.10 on Friday, reaching $14.60. The company had a trading volume of 165,671 shares, compared to its average volume of 233,711. Atara Biotherapeutics, Inc. has a 1 year low of $11.80 and a 1 year high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). analysts forecast that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Gad Soffer Sells 7,000 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/gad-soffer-sells-7000-shares-of-atara-biotherapeutics-inc-atra-stock/1710477.html.
A number of hedge funds and other institutional investors have recently modified their holdings of ATRA. SG Americas Securities LLC purchased a new stake in Atara Biotherapeutics during the 3rd quarter worth about $142,000. Voya Investment Management LLC increased its holdings in Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. Russell Investments Group Ltd. purchased a new stake in Atara Biotherapeutics during the 3rd quarter worth about $170,000. State of Wisconsin Investment Board purchased a new stake in Atara Biotherapeutics during the 2nd quarter worth about $252,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. Institutional investors own 82.95% of the company’s stock.
ATRA has been the topic of several recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of “Hold” and an average price target of $24.40.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.